| Title |
The Chronic Myeloid Leukemia (CML) Registry of the GQR-LMC |
| Protocole ID |
MP-HMR-09-001 |
| ClinicalTrials.gov ID |
|
| Cancer Type(s) |
Chronic Myeloid Leukemia |
| Phase |
Other |
| Stage |
|
| Study Type |
|
| Drug |
|
| Institution |
CISSS DE LAVAL
 HOPITAL DE LA CITE-DE-LA-SANTE
1755 boul. René-Laennec, Laval, QC, H7M 3L9
|
| City |
Laval |
| Principal Investigator |
Dr. Danielle Talbot
|
| Coordinator |
Solange Tremblay
450-668-1010 poste 23603
|
| Status |
Recruiting |
| Activation Date |
|
| Eligibility Criteria |
All patients in Canada who meet the following inclusion criteria may be enrolled in the CML
Registry:
-
have a clinical diagnosis of CML;
-
are 18 years of age or older;
-
are able to give written, informed consent (or have a legal representative who can give written, informed consent when applicable).
|
| Exclusion Criteria |
Patients who meet any of the following criteria will be excluded from participation:
-
unwilling or unable to give written, informed consent;
-
under 18 years of age;
-
life expectancy of 3 months for a condition not related to CML
|
| |
|
Groupe d'étude en oncologie du Québec